MX2022005649A - Compuesto y farmaco de azabencimidazol. - Google Patents

Compuesto y farmaco de azabencimidazol.

Info

Publication number
MX2022005649A
MX2022005649A MX2022005649A MX2022005649A MX2022005649A MX 2022005649 A MX2022005649 A MX 2022005649A MX 2022005649 A MX2022005649 A MX 2022005649A MX 2022005649 A MX2022005649 A MX 2022005649A MX 2022005649 A MX2022005649 A MX 2022005649A
Authority
MX
Mexico
Prior art keywords
compound
present
bladder
medicine
pam
Prior art date
Application number
MX2022005649A
Other languages
English (en)
Inventor
Sho Hirai
Kazuhiko Wakita
Koya OIKAWA
Takuto YAMANAKA
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of MX2022005649A publication Critical patent/MX2022005649A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

El propósito de la presente invención es proporcionar un compuesto que tiene actividad PAM M3. Los ejemplos de la presente invención incluyen compuestos de azabencimidazol representados por la siguiente fórmula [1] y sales farmacéuticamente aceptables del mismo. (ver Fórmula) [1] Los compuestos de la presente invención tienen actividad de PAM M3. Además, dado que los compuestos de la presente invención tienen actividad de PAM M3, los compuestos de la presente invención son útiles como agentes preventivos o agentes terapéuticos para trastornos de micción y trastornos de acumulación de orina en vejiga hipoactiva, vejiga hipotónica, vejiga acontráctil, hipoactividad del detrusor y vejiga neurogénica.
MX2022005649A 2019-11-13 2020-11-12 Compuesto y farmaco de azabencimidazol. MX2022005649A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019205344 2019-11-13
PCT/JP2020/042247 WO2021095801A1 (ja) 2019-11-13 2020-11-12 アザベンゾイミダゾール化合物及び医薬

Publications (1)

Publication Number Publication Date
MX2022005649A true MX2022005649A (es) 2022-06-22

Family

ID=75912665

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005649A MX2022005649A (es) 2019-11-13 2020-11-12 Compuesto y farmaco de azabencimidazol.

Country Status (11)

Country Link
US (1) US20230002395A1 (es)
EP (1) EP4059933A4 (es)
JP (1) JPWO2021095801A1 (es)
KR (1) KR20220100627A (es)
CN (1) CN114929697A (es)
AU (1) AU2020384041A1 (es)
BR (1) BR112022008571A2 (es)
CA (1) CA3161582A1 (es)
MX (1) MX2022005649A (es)
TW (1) TW202128689A (es)
WO (1) WO2021095801A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023017813A1 (en) * 2021-08-10 2023-02-16 Ono Pharmaceutical Co., Ltd. Process for making an ep4 antagonist

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523957A (ja) 2004-02-25 2007-08-23 スミスクライン・ビーチャム・コーポレイション 新規化学化合物
ES2274712B1 (es) * 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
JP2013237634A (ja) * 2012-05-14 2013-11-28 Dainippon Sumitomo Pharma Co Ltd 縮環イミダゾロン誘導体
CN111094250B (zh) * 2017-03-03 2022-11-04 江苏豪森药业集团有限公司 凋亡信号调节激酶抑制剂及其制备方法和应用
WO2019216294A1 (ja) * 2018-05-08 2019-11-14 日本新薬株式会社 アザベンゾイミダゾール化合物及び医薬

Also Published As

Publication number Publication date
WO2021095801A1 (ja) 2021-05-20
CA3161582A1 (en) 2021-05-20
TW202128689A (zh) 2021-08-01
AU2020384041A1 (en) 2022-06-09
EP4059933A1 (en) 2022-09-21
JPWO2021095801A1 (es) 2021-05-20
EP4059933A4 (en) 2023-11-15
BR112022008571A2 (pt) 2022-08-09
CN114929697A (zh) 2022-08-19
KR20220100627A (ko) 2022-07-15
US20230002395A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
EP3569601A3 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
MX2020011910A (es) Compuestos de heteroarilo tetraciclicos.
MX2020013817A (es) Compuestos de naftiridinona sustituidos utiles como activadores de celulas t.
MX2023007192A (es) Inhibidores de prmt5.
EP4306529A3 (en) Fgfr inhibitors and methods of use thereof
PH12014502041A1 (en) Heterocyclyl compounds as mek inhibitors
BR112022010254A2 (pt) Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
MX2015012760A (es) Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma.
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
NZ612000A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
NZ630719A (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
GEP20227434B (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
MX2022008103A (es) Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
WO2018201167A3 (en) Propionic acid derivatives and methods of use thereof
PH12020551555A1 (en) Calpain modulators and therapeutic uses thereof
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
PH12020551873A1 (en) Azabenzimidazole compounds and pharmaceutical
MX2022005649A (es) Compuesto y farmaco de azabencimidazol.